Metformin: Uses, Dosage & Side Effects
The first-line oral antidiabetic medication for type 2 diabetes mellitus, belonging to the biguanide class
Metformin is the most widely prescribed oral medication for type 2 diabetes mellitus worldwide. It belongs to the biguanide class of antidiabetic agents and works by reducing hepatic glucose production, decreasing intestinal glucose absorption, and improving insulin sensitivity. Metformin is recommended as the first-line pharmacological therapy by virtually all major diabetes guidelines, including the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and the World Health Organization (WHO). It is listed on the WHO Model List of Essential Medicines and requires a prescription in most countries.
Quick Facts: Metformin
Key Takeaways
- Metformin is the recommended first-line oral medication for type 2 diabetes by the ADA, EASD, WHO, and NICE, used when diet and exercise alone are insufficient to control blood glucose levels.
- Unlike sulfonylureas and insulin, metformin does not cause hypoglycemia when used alone and is associated with stable body weight or modest weight loss, making it particularly suitable for overweight patients.
- The most common side effects are gastrointestinal (nausea, diarrhea, abdominal pain), which typically improve over time and can be minimized by taking the medication with food and gradually increasing the dose.
- Lactic acidosis is a very rare but potentially life-threatening complication; risk is increased with kidney impairment, dehydration, liver disease, severe infection, and excessive alcohol intake.
- Metformin must be temporarily stopped before imaging procedures involving iodinated contrast media and before major surgery; your doctor will advise when to restart.
What Is Metformin and What Is It Used For?
Metformin is the most widely prescribed medication for type 2 diabetes mellitus worldwide, with over 150 million prescriptions filled annually. First introduced for clinical use in 1957 in France and approved by the U.S. Food and Drug Administration (FDA) in 1995, it has become the cornerstone of diabetes management recommended by virtually every international diabetes guideline. The World Health Organization includes metformin on its Model List of Essential Medicines, reflecting its critical importance in global healthcare.
The medication works through multiple mechanisms of action. Its primary effect is the reduction of hepatic glucose production (gluconeogenesis), which is abnormally elevated in type 2 diabetes. Metformin activates AMP-activated protein kinase (AMPK), a cellular energy sensor that plays a key role in regulating glucose and fat metabolism. In addition, it decreases the absorption of glucose from the intestinal tract and enhances peripheral glucose uptake and utilization by improving insulin sensitivity in muscle and adipose tissue.
Importantly, metformin differs from sulfonylureas and other insulin secretagogues in that it does not directly stimulate insulin secretion from the pancreatic beta cells. This means that when used as monotherapy (without other diabetes medications), it does not cause hypoglycemia (abnormally low blood sugar), which is a significant safety advantage. It is also associated with stable body weight or a modest reduction in weight, unlike many other antidiabetic drugs that promote weight gain.
Metformin is used to treat patients with type 2 diabetes (also called non-insulin-dependent diabetes mellitus) when dietary changes and regular physical exercise are insufficient to achieve adequate blood glucose control. It is particularly recommended for overweight and obese patients, as the landmark United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that metformin reduces the risk of diabetes-related complications and cardiovascular mortality in this population. Adults can use metformin as a single therapy (monotherapy) or in combination with other oral antidiabetic drugs (such as sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, or thiazolidinediones) or with injectable insulin.
Children aged 10 years and older and adolescents may also be prescribed metformin, either as monotherapy or in combination with insulin, for the treatment of type 2 diabetes. Treatment in children aged 10 to 12 years is recommended only under specialist supervision due to limited clinical experience in this age group. Metformin is available as film-coated tablets in strengths of 500 mg, 850 mg, and 1000 mg, as well as in extended-release formulations in some markets.
What Should You Know Before Taking Metformin?
Contraindications
There are specific clinical situations where metformin must not be used. Understanding these contraindications is essential for safe medication use and the prevention of serious adverse events, particularly lactic acidosis. You should not take metformin if any of the following apply:
- Allergy to metformin: Known hypersensitivity to metformin hydrochloride or any excipient in the formulation.
- Severe kidney impairment: Severely reduced kidney function (eGFR below 30 mL/min/1.73 m²), as the kidneys are the primary route of metformin elimination and impaired clearance significantly increases the risk of lactic acidosis.
- Liver problems: Hepatic insufficiency or active liver disease, as the liver plays a critical role in lactate metabolism.
- Uncontrolled diabetes: Severe hyperglycemia with diabetic ketoacidosis (DKA), nausea, vomiting, diarrhea, or rapid weight loss. Ketoacidosis is a metabolic emergency characterized by accumulation of ketone bodies in the blood.
- Severe dehydration: For example from prolonged or severe diarrhea, repeated vomiting, or inadequate fluid intake. Dehydration can impair kidney function and precipitate lactic acidosis.
- Severe infection: Particularly infections affecting the lungs, airways, or urinary tract, which can compromise kidney function.
- Acute heart failure or recent heart attack: Conditions associated with acute cardiovascular collapse, circulatory shock, or respiratory failure that may lead to tissue hypoxia.
- Excessive alcohol intake: Chronic heavy alcohol use increases the risk of lactic acidosis by impairing hepatic lactate clearance.
Warnings and Precautions
Metformin can cause lactic acidosis, a very rare but very serious metabolic complication. The risk is highest in patients with impaired kidney function, uncontrolled diabetes, severe infections, prolonged fasting, excessive alcohol intake, dehydration, liver disease, and conditions with reduced tissue oxygenation. Stop metformin immediately and seek emergency medical attention if you experience: vomiting, abdominal pain, muscle cramps, general malaise with extreme fatigue, difficulty breathing, or decreased body temperature and heart rate.
Lactic acidosis occurs when lactate accumulates in the blood faster than the body can clear it, leading to a dangerous drop in blood pH. While extremely rare when metformin is used appropriately (estimated incidence of 3-10 cases per 100,000 patient-years), lactic acidosis carries a mortality rate of approximately 30-50% and is considered a medical emergency requiring immediate hospitalization. The risk can be minimized by adhering to contraindications, monitoring kidney function regularly, and temporarily discontinuing metformin during acute illness.
You should temporarily stop taking metformin and consult your doctor if you develop a condition that may lead to dehydration, such as severe vomiting, diarrhea, fever, or reduced fluid intake. Dehydration can cause acute kidney injury, which impairs metformin clearance and increases the risk of lactic acidosis. Your doctor will advise you when it is safe to restart the medication.
You must stop taking metformin before imaging procedures involving injection of iodinated contrast media (such as CT scans or angiography) and before major surgery under general anesthesia. Contrast agents can temporarily impair kidney function, and major surgery may affect tissue oxygenation. Your doctor will determine when to stop metformin and when it is safe to resume treatment, typically 48 hours after the procedure once kidney function has been confirmed as adequate.
Your doctor will monitor your kidney function at least once per year, or more frequently if you are elderly or if your kidney function is at the lower end of normal. Metformin dose adjustments are required for moderate kidney impairment (eGFR 30-60 mL/min/1.73 m²), and the medication should be discontinued if eGFR falls below 30 mL/min/1.73 m².
When used alone, metformin does not cause hypoglycemia. However, when combined with other antidiabetic medications that can lower blood sugar (such as sulfonylureas, meglitinides, or insulin), there is a risk of hypoglycemia. Symptoms include weakness, dizziness, increased sweating, rapid heartbeat, visual disturbances, and difficulty concentrating. If you experience these symptoms, consuming something containing sugar (such as fruit juice or glucose tablets) usually helps promptly.
Speak to your doctor immediately if you have a genetically inherited mitochondrial disease such as MELAS syndrome (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) or MIDD (maternally inherited diabetes and deafness). Also contact your doctor if you develop seizures, impaired cognitive function, movement disorders, symptoms suggesting nerve damage (such as pain or numbness), migraine, or hearing loss after starting metformin treatment.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, you should speak with your doctor about appropriate changes to your diabetes treatment. Uncontrolled blood glucose during pregnancy carries risks for both the mother and the developing baby. While some clinical data suggest metformin may be used in pregnancy under careful medical supervision (particularly for gestational diabetes and polycystic ovary syndrome), insulin remains the preferred treatment for diabetes during pregnancy in most international guidelines, as it does not cross the placenta.
Metformin passes into breast milk in small amounts. Because the potential effects on the nursing infant are not fully established, breastfeeding is generally not recommended during metformin therapy, or your doctor may advise you to stop breastfeeding while taking this medication. Discuss the risks and benefits with your healthcare provider.
Driving and Operating Machinery
Metformin alone does not cause hypoglycemia and therefore does not impair your ability to drive or operate machinery. However, you should exercise particular caution if you take metformin in combination with other diabetes medications that can cause hypoglycemia (such as sulfonylureas, insulin, or meglitinides). Symptoms of hypoglycemia, including weakness, dizziness, visual disturbances, and difficulty concentrating, can significantly impair your ability to drive safely or operate equipment.
How Does Metformin Interact with Other Drugs?
Drug interactions with metformin can occur through several mechanisms: some medications increase the risk of lactic acidosis by impairing kidney function, others affect blood glucose levels, and certain drugs alter the blood concentration of metformin itself. It is essential to inform your healthcare provider about all medications you are taking, including prescription drugs, over-the-counter medicines, and dietary supplements.
Major Interactions
| Interacting Drug | Effect | Action Required |
|---|---|---|
| Iodinated contrast media | Can impair kidney function, increasing lactic acidosis risk | Stop metformin before or at the time of contrast injection; restart 48 hours later after confirming normal kidney function |
| Alcohol | Increases risk of lactic acidosis and hypoglycemia; impairs hepatic lactate clearance | Avoid excessive alcohol intake; never binge drink while on metformin |
| Diuretics | May cause dehydration and impair kidney function | Monitor kidney function closely; adjust doses as needed |
| NSAIDs (ibuprofen, celecoxib) | Can impair kidney function, increasing lactic acidosis risk | Use with caution; monitor kidney function during concurrent use |
| ACE inhibitors / ARBs | May affect kidney function | Monitor kidney function and blood glucose regularly |
Other Notable Interactions
| Interacting Drug | Effect | Action Required |
|---|---|---|
| Corticosteroids | Can raise blood glucose levels, reducing metformin effectiveness | Monitor blood glucose more frequently; dose adjustment may be needed |
| Beta-2 agonists (salbutamol, terbutalin) | Can raise blood glucose levels | Monitor blood glucose; may need temporary insulin |
| Cimetidine | Increases metformin blood levels by competing for renal tubular secretion | Consider alternative acid suppressant or dose adjustment |
| Dolutegravir | Increases metformin blood levels via OCT2 inhibition | Consider reducing metformin dose when starting or stopping dolutegravir |
| Verapamil, rifampicin, ranolazine, trimethoprim | May alter metformin blood levels, especially with impaired kidney function | Monitor blood glucose and kidney function; adjust metformin dose if needed |
| Other antidiabetic drugs (sulfonylureas, insulin) | Increased risk of hypoglycemia when combined | Monitor blood glucose closely; dose reduction of the other drug may be needed |
This list is not exhaustive. Always tell your doctor or pharmacist about all medicines you are taking, have recently taken, or might take. Your doctor may need to perform more frequent blood glucose and kidney function tests or adjust your metformin dose accordingly.
What Is the Correct Dosage of Metformin?
Always take metformin exactly as your doctor has prescribed. The dose is individualized based on your blood glucose levels, kidney function, and response to treatment. Your doctor will typically start with a low dose and gradually increase it to minimize gastrointestinal side effects. Do not adjust your dose without medical advice.
Adults
Adult Dosage (18 years and over)
- Starting dose: 500 mg or 850 mg, taken two or three times daily
- Dose adjustment: Increase by 500 mg every 1-2 weeks based on blood glucose response
- Usual maintenance dose: 1,500-2,000 mg per day in divided doses
- Maximum daily dose: 3,000 mg, divided into three doses
The dose of metformin is typically increased gradually (dose titration) to minimize gastrointestinal side effects, which are most common during the first few weeks of treatment. If you are overweight and have type 2 diabetes, long-term use of metformin has been shown to reduce the risk of diabetes-related complications. The UKPDS study demonstrated a 32% reduction in diabetes-related endpoints and a 42% reduction in diabetes-related death in overweight patients treated with metformin compared to conventional dietary management alone.
Children (10 years and over)
Pediatric Dosage (10-17 years)
- Starting dose: 500 mg or 850 mg, taken once daily
- Dose adjustment: Increase gradually based on blood glucose response
- Maximum daily dose: 2,000 mg, divided into two or three doses
Treatment of children aged 10 to 12 years is recommended only on the specific advice of their doctor, as clinical experience in this age group is limited. Children and adolescents can take metformin as monotherapy or in combination with insulin. Regular medical follow-up, including blood glucose monitoring and kidney function tests, is particularly important in younger patients.
Elderly Patients and Kidney Impairment
Dose Adjustments for Kidney Function
- eGFR 45-60 mL/min: No dose adjustment usually needed; review kidney function every 3-6 months
- eGFR 30-45 mL/min: Maximum dose 1,000 mg per day; review kidney function every 3 months
- eGFR below 30 mL/min: Metformin must not be used
Elderly patients often have reduced kidney function, which may not be apparent from serum creatinine values alone. Therefore, kidney function (eGFR) should be assessed at least twice per year in elderly patients taking metformin. Your doctor will determine the appropriate dose based on your kidney function and may prescribe a lower dose to ensure safe use.
How to Take Metformin
Take metformin with or immediately after a meal. This helps to reduce gastrointestinal side effects such as nausea, diarrhea, and abdominal pain. Swallow the tablets whole with a glass of water; do not crush or chew them. The 1000 mg tablet can be divided into two equal halves along the score line if needed.
- One dose daily: Take it in the morning with breakfast.
- Two doses daily: Take one in the morning (breakfast) and one in the evening (dinner).
- Three doses daily: Take one at breakfast, one at lunch, and one at dinner.
Metformin cannot replace the benefits of a healthy lifestyle. Continue to follow any dietary advice your doctor has given you and exercise regularly. If you also take insulin, your doctor will tell you how to start metformin treatment and may need to adjust your insulin dose.
Missed Dose
If you forget to take a dose of metformin, take the next dose at the usual time. Do not take a double dose to make up for a missed one. Maintaining a consistent schedule helps keep your blood glucose levels stable.
Overdose
If you have taken too much metformin, lactic acidosis may occur. Symptoms include vomiting, abdominal pain with muscle cramps, a general feeling of being unwell with severe fatigue, and difficulty breathing. Additional symptoms may include decreased body temperature and heart rate. If you experience any of these symptoms, seek emergency medical attention immediately, as lactic acidosis can lead to coma. Stop taking metformin and contact your doctor or go to the nearest emergency department without delay.
Hypoglycemia (low blood sugar) has not been observed with metformin doses up to 85 g (far exceeding the maximum therapeutic dose), although lactic acidosis has occurred under such circumstances. Metformin overdose can also contribute to acute kidney injury. In cases of severe overdose, hemodialysis may be necessary to remove metformin from the bloodstream, as metformin is dialyzable due to its lack of protein binding.
What Are the Side Effects of Metformin?
Like all medicines, metformin can cause side effects, although not everyone experiences them. The most frequently reported side effects are gastrointestinal in nature and typically occur during the initial weeks of treatment. These often improve as the body adjusts to the medication. Distributing doses throughout the day and taking metformin with or immediately after meals can help reduce these effects. If gastrointestinal symptoms persist or become severe, speak with your doctor.
Very Common
May affect more than 1 in 10 people
- Nausea and vomiting
- Diarrhea
- Abdominal pain and stomach cramps
- Loss of appetite (anorexia)
Common
May affect up to 1 in 10 people
- Taste disturbances (metallic taste)
- Decreased or low vitamin B12 levels in the blood, which may cause extreme fatigue, sore red tongue (glossitis), tingling (paresthesia), or pale/yellowish skin
Very Rare
May affect up to 1 in 10,000 people
- Lactic acidosis — a very serious complication, especially if kidneys are not functioning properly. Symptoms include vomiting, abdominal pain, muscle cramps, severe fatigue, and difficulty breathing. Seek emergency medical attention immediately.
- Abnormal liver function tests or hepatitis (liver inflammation), which may cause fatigue, loss of appetite, weight loss, with or without yellowing of the skin or eyes
- Skin reactions: redness (erythema), itching (pruritus), or hives (urticaria)
Vitamin B12 Deficiency
Long-term use of metformin has been consistently associated with decreased vitamin B12 absorption, which can lead to clinically significant B12 deficiency in approximately 5-10% of patients. This is thought to occur through metformin's interference with the calcium-dependent absorption of the vitamin B12-intrinsic factor complex in the terminal ileum. Symptoms of B12 deficiency may develop gradually and include extreme tiredness, a sore and red tongue, mouth ulcers, muscle weakness, disturbed vision, pins and needles (peripheral neuropathy), and psychological problems such as depression or confusion.
Because the symptoms of B12 deficiency can mimic or overlap with diabetic neuropathy, it is important for patients on long-term metformin therapy to have their B12 levels checked periodically, typically every 1-2 years. If B12 deficiency is detected, supplementation with oral or intramuscular vitamin B12 effectively corrects the deficiency in most cases. Your doctor may recommend routine B12 monitoring, particularly if you have been taking metformin for several years or if you develop symptoms of neuropathy.
Children and Adolescents
Limited clinical data indicate that the type and severity of side effects in children and adolescents are similar to those observed in adults. The gastrointestinal effects are the most commonly reported and can usually be managed through dose titration and administration with food.
How Should You Store Metformin?
No special storage conditions are required for metformin film-coated tablets. Store them at room temperature, protected from excessive heat, moisture, and direct light. Keep the tablets in their original packaging (blister pack or container) until ready to use.
Keep this medication out of the sight and reach of children. If a child is being treated with metformin, parents and caregivers should supervise the use of this medication to ensure proper dosing and safety. Do not use the medicine after the expiry date printed on the carton, bottle, or blister pack (the expiry date refers to the last day of the stated month).
Do not dispose of medications in wastewater or household waste. Return unused or expired medications to your pharmacy for safe disposal. These measures help protect the environment and prevent accidental exposure.
What Does Metformin Contain?
Metformin tablets contain the active substance metformin hydrochloride. The hydrochloride salt form provides optimal stability and bioavailability. Each tablet strength delivers a corresponding amount of metformin base:
| Tablet Strength | Metformin HCl | Metformin Base Equivalent |
|---|---|---|
| 500 mg | 500 mg | 390 mg |
| 850 mg | 850 mg | 662.9 mg |
| 1000 mg | 1000 mg | 780 mg |
The inactive ingredients (excipients) in metformin film-coated tablets typically include:
- Tablet core: Povidone K 30 (binding agent), magnesium stearate (lubricant)
- Film coating: Hypromellos (hydroxypropyl methylcellulose). The 1000 mg tablet also contains macrogol 400 and macrogol 8000 in the coating.
The tablets are white, round (500 mg and 850 mg) or oval (1000 mg) in shape. The 1000 mg tablets are biconvex with a score line on both sides, allowing them to be divided into two equal halves. The exact appearance may vary between different manufacturers and brands. If you have allergies to any excipients, review the full ingredients list on the patient information leaflet supplied with your specific product.
Frequently Asked Questions About Metformin
Metformin is the first-line medication for the treatment of type 2 diabetes mellitus. It works by reducing the liver's glucose production, decreasing intestinal glucose absorption, and improving insulin sensitivity in muscle tissue. It is used when diet and exercise alone are not enough to control blood sugar levels. Adults can take metformin alone or in combination with other diabetes medications, including insulin. It is particularly beneficial for overweight patients, as it does not cause weight gain.
The most common side effects are gastrointestinal and include nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. These effects typically occur when starting treatment and often improve after the first few weeks as the body adjusts. Taking metformin with or immediately after food and starting with a low dose that is gradually increased can help minimize these symptoms. Taste changes (metallic taste) and vitamin B12 deficiency are also commonly reported.
Lactic acidosis is a very rare but very serious metabolic emergency that can occur with metformin, particularly in patients with impaired kidney function. It happens when lactate accumulates faster than the body can clear it. Symptoms include vomiting, abdominal pain, muscle cramps, general malaise with extreme fatigue, difficulty breathing, and decreased body temperature and heart rate. If you experience these symptoms, stop metformin immediately and seek emergency medical care. The risk is minimized by monitoring kidney function regularly and avoiding metformin when contraindicated.
Metformin is considered weight-neutral or associated with modest weight loss. Unlike many other diabetes medications (such as sulfonylureas, thiazolidinediones, and insulin), metformin typically does not cause weight gain. Clinical studies, including the Diabetes Prevention Program, have shown that metformin may lead to a modest weight reduction of approximately 1-3 kg. This weight neutrality is one of the key reasons it is recommended as the first-line therapy for type 2 diabetes, particularly in overweight and obese patients.
Yes. Iodinated contrast media used in CT scans and certain other imaging procedures can temporarily impair kidney function. Since the kidneys are responsible for eliminating metformin from the body, reduced kidney function increases the risk of metformin accumulation and lactic acidosis. You must stop metformin before or at the time of the contrast injection. Your doctor will typically instruct you to restart metformin 48 hours after the procedure, once a blood test has confirmed that your kidney function is normal.
You should avoid excessive alcohol consumption while taking metformin. Alcohol impairs the liver's ability to clear lactate and can increase the risk of lactic acidosis, particularly during prolonged fasting or binge drinking. Alcohol can also cause hypoglycemia when combined with diabetes medications. While occasional moderate alcohol intake may be acceptable for some patients, you should discuss your alcohol consumption with your doctor, who can advise you based on your individual health situation and kidney function.
References
This article is based on current international medical guidelines and peer-reviewed scientific literature. All medical claims are supported by evidence level 1A, the highest quality of evidence based on systematic reviews and randomized controlled trials.
- American Diabetes Association (ADA). Standards of Medical Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1). Comprehensive annual guidelines for the management of diabetes mellitus.
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865. doi:10.1016/S0140-6736(98)07037-8
- European Medicines Agency (EMA). Glucophage (metformin hydrochloride) — Summary of Product Characteristics. Updated 2025. Official European regulatory document for metformin.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List (2023). Geneva: WHO; 2023. Metformin is listed as an essential medicine for the treatment of diabetes.
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG28). Updated 2024. UK clinical guidelines recommending metformin as first-line therapy.
- DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333(9):541-549. doi:10.1056/NEJM199508313330902
- Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. doi:10.1056/NEJMoa012512
- Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754-1761. doi:10.1210/jc.2015-3754
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and EASD. Diabetes Care. 2022;45(11):2753-2786. doi:10.2337/dci22-0034
- Lalau JD, Kajbaf F, Protti A, et al. Metformin-associated lactic acidosis (MALA): Moving towards a new paradigm. Diabetes Obes Metab. 2017;19(11):1502-1512. doi:10.1111/dom.12974
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians with specialist qualifications in endocrinology, clinical pharmacology, and internal medicine. All content follows the GRADE evidence framework and adheres to international medical standards set by the WHO, EMA, FDA, and ADA.
All articles undergo a rigorous multi-step review process: initial drafting by medical writers, clinical accuracy review by specialist physicians, evidence grading according to the GRADE framework, and final editorial quality assurance. Content is updated regularly to reflect new guidelines, research findings, and safety information.
iMedic follows Evidence Level 1A standards, drawing from systematic reviews, meta-analyses, and randomized controlled trials published in peer-reviewed journals. We reference established clinical guidelines from international medical organizations including the ADA, EASD, WHO, EMA, FDA, and NICE.
For questions about our editorial process or to report inaccuracies, please visit our Editorial Standards page or contact our editorial team.